AtriCure earns CE Mark for left atrial appendage exclusion system
AtriCure, a developer of cardiac surgical ablation systems, has received CE Mark approval for its AtriClip Gillinov-Cosgrove left atrial appendage exclusion system.
According to the West Chester, Ohio-based company, the AtriClip System is designed to safely exclude the left atrial appendage, and is being launched in Europe through a phased approach during the fourth quarter. The full commercial release in Europe is planned for 2010. Trials are underway for FDA approval as well.
According to the West Chester, Ohio-based company, the AtriClip System is designed to safely exclude the left atrial appendage, and is being launched in Europe through a phased approach during the fourth quarter. The full commercial release in Europe is planned for 2010. Trials are underway for FDA approval as well.